|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hieken TJ, Carter JM, Hawse JR, Hoskin TL,
Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW and Degnim
AC: ERβ expression and breast cancer risk prediction for women with
atypias. Cancer Prev Res (Phila). 8:1084–1092. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Roger P, Sahla ME, Mäkelä S, Gustafsson
JA, Baldet P and Rochefort H: Decreased expression of estrogen
receptor beta protein in proliferative preinvasive mammary tumors.
Cancer Res. 61:2537–2541. 2001.PubMed/NCBI
|
|
5
|
Shaw JA, Udokang K, Mosquera JM, Chauhan
H, Jones JL and Walker RA: Oestrogen receptors alpha and beta
differ in normal human breast and breast carcinomas. J Pathol.
198:450–457. 2002.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Huang B, Omoto Y, Iwase H, Yamashita H,
Toyama T, Coombes RC, Filipovic A, Warner M and Gustafsson JÅ:
Differential expression of estrogen receptor α, β1, and β2 in
lobular and ductal breast cancer. Proc Natl Acad Sci USA.
111:1933–1938. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Reese JM, Suman VJ, Subramaniam M, Wu X,
Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE,
et al: ERβ1: Characterization, prognosis, and evaluation of
treatment strategies in ERα-positive and -negative breast cancer.
BMC Cancer. 14(749)2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang J, Zhang C, Chen K, Tang H, Tang J,
Song C and Xie X: ERβ1 inversely correlates with PTEN/PI3K/AKT
pathway and predicts a favorable prognosis in triple-negative
breast cancer. Breast Cancer Res Treat. 152:255–269.
2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Dey P, Wang A, Ziegler Y, Kumar S, Yan S,
Kim SH, Katzenellenbogen JA and Katzenellenbogen BS: Estrogen
receptor beta 1: A potential therapeutic target for female triple
negative breast cancer. Endocrinology. 163(bqac172)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao L, Huang S, Mei S, Yang Z, Xu L, Zhou
N, Yang Q, Shen Q, Wang W, Le X, et al: Pharmacological activation
of estrogen receptor beta augments innate immunity to suppress
cancer metastasis. Proc Natl Acad Sci USA. 115:E3673–E3681.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Reese JM, Bruinsma ES, Nelson AW,
Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V,
Monroe DG, et al: ERβ-mediated induction of cystatins results in
suppression of TGFβ signaling and inhibition of triple-negative
breast cancer metastasis. Proc Natl Acad Sci USA. 115:E9580–E9589.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mehraj U, Qayoom H and Mir MA: Prognostic
significance and targeting tumor-associated macrophages in cancer:
New insights and future perspectives. Breast Cancer. 28:539–555.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Williams CB, Yeh ES and Soloff AC:
Tumor-associated macrophages: Unwitting accomplices in breast
cancer malignancy. NPJ Breast Cancer. 2(15025)2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Miyasato Y, Shiota T, Ohnishi K, Pan C,
Yano H, Horlad H, Yamamoto Y, Yamamoto-Ibusuki M, Iwase H, Takeya M
and Komohara Y: High density of CD204-positive macrophages predicts
worse clinical prognosis in patients with breast cancer. Cancer
Sci. 108:1693–1700. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ning C, Xie B, Zhang L, Li C, Shan W, Yang
B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce
ERα expression through an IL17A-mediated epigenetic mechanism to
sensitize endometrial cancer cells to estrogen. Cancer Res.
76:1354–1366. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Stossi F, Madak-Erdoğan Z and
Katzenellenbogen BS: Macrophage-elicited loss of estrogen
receptor-α in breast cancer cells via involvement of MAPK and c-Jun
at the ESR1 genomic locus. Oncogene. 31:1825–1834. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang Q, Le K, Xu M, Zhou J, Xiao Y, Yang
W, Jiang Y, Xi Z and Huang T: Combined MEK inhibition and
tumor-associated macrophages depletion suppresses tumor growth in a
triple-negative breast cancer mouse model. Int Immunopharmacol.
76(105864)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chung H, Gyu-Mi P, Na YR, Lee YS, Choi H
and Seok SH: Comprehensive characterization of early-programmed
tumor microenvironment by tumor-associated macrophages reveals
galectin-1 as an immune modulatory target in breast cancer.
Theranostics. 14:843–860. 2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jiang H, Fan D, Zhou G, Li X and Deng H:
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis
of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin
Cancer Res. 29(34)2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fujiwara M, Izuishi K, Sano T, Hossain MA,
Kimura S, Masaki T and Suzuki Y: Modulating effect of the
PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic
cancer cells. J Exp Clin Cancer Res. 27(76)2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Guo D, Liu X, Zeng C, Cheng L, Song G, Hou
X, Zhu L and Zou K: Estrogen receptor β activation ameliorates
DSS-induced chronic colitis by inhibiting inflammation and
promoting Treg differentiation. Int Immunopharmacol.
77(105971)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ghandi M, Huang FW, Jané-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
cancer cell line encyclopedia. Nature. 569:503–508. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357(eaan2507)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48 (W1):W509–W514. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang B, Guo X, Huang L, Zhang Y, Li Z, Su
D, Lin L, Zhou P, Ye H, Lu Y and Zhou Q: Tumour-associated
macrophages and Schwann cells promote perineural invasion via
paracrine loop in pancreatic ductal adenocarcinoma. Br J Cancer.
130:542–554. 2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang L, Lu X, Xu Y, La X, Tian J, Li A,
Li H, Wu C, Xi Y, Song G, et al: Tumor-associated macrophages
confer colorectal cancer 5-fluorouracil resistance by promoting
MRP1 membrane translocation via an intercellular
CXCL17/CXCL22-CCR4-ATF6-GRP78 axis. Cell Death Dis.
14(582)2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Qin Q, Ji H, Li D, Zhang H, Zhang Z and
Zhang Q: Tumor-associated macrophages increase COX-2 expression
promoting endocrine resistance in breast cancer via the
PI3K/Akt/mTOR pathway. Neoplasma. 68:938–946. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yu X, Wang R, Zhang Y, Zhou L, Wang W, Liu
H and Li W: Skp2-mediated ubiquitination and mitochondrial
localization of Akt drive tumor growth and chemoresistance to
cisplatin. Oncogene. 38:7457–7472. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jia X, Li C, Li L, Liu X, Zhou L, Zhang W,
Ni S, Lu Y, Chen L, Jeong LS, et al: Neddylation inactivation
facilitates FOXO3a nuclear export to suppress estrogen receptor
transcription and improve fulvestrant sensitivity. Clin Cancer Res.
25:3658–3672. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hammershoi Madsen AM, Lovendahl Eefsen RH,
Nielsen D and Kumler I: Targeted treatment of metastatic
triple-negative breast cancer: A systematic review. Breast J.
2024(9083055)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hwang NM and Stabile LP: Estrogen receptor
ß in cancer: To ß(e) or not to ß(e)? Endocrinology.
162(bqab162)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shanle EK, Zhao Z, Hawse J, Wisinski K,
Keles S, Yuan M and Xu W: Research resource: global identification
of estrogen receptor β target genes in triple negative breast
cancer cells. Mol Endocrinol. 27:1762–1775. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hinsche O, Girgert R, Emons G and Gründker
C: Estrogen receptor β selective agonists reduce invasiveness of
triple-negative breast cancer cells. Int J Oncol. 46:878–884.
2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wisinski KB, Xu W, Tevaarwerk AJ, Saha S,
Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, et al:
Targeting estrogen receptor beta in a phase 2 study of high-dose
estradiol in metastatic triple-negative breast cancer: A wisconsin
oncology network study. Clin Breast Cancer. 16:256–261.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gao L, Qi X, Hu K, Zhu R, Xu W, Sun S,
Zhang L, Yang X, Hua B and Liu G: Estrogen receptor β promoter
methylation: A potential indicator of malignant changes in breast
cancer. Arch Med Sci. 12:129–136. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ireland L, Santos A, Campbell F,
Figueiredo C, Hammond D, Ellies LG, Weyer-Czernilofsky U,
Bogenrieder T, Schmid M and Mielgo A: Blockade of insulin-like
growth factors increases efficacy of paclitaxel in metastatic
breast cancer. Oncogene. 37:2022–2036. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fang C, Cheung MY, Chan RC, Poon IK, Lee
C, To CC, Tsang JY, Li J and Tse GM: Prognostic significance of
CD163+ and/or CD206+ tumor-associated macrophages is linked to
their spatial distribution and tumor-infiltrating lymphocytes in
breast cancer. Cancers (Basel). 16(2147)2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pascual J and Turner NC: Targeting the
PI3-kinase pathway in triple-negative breast cancer. Ann Oncol.
30:1051–1060. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shen K, Yu H, Xie B, Meng Q, Dong C, Shen
K and Zhou HB: Anticancer or carcinogenic? The role of estrogen
receptor β in breast cancer progression. Pharmacol Ther.
242(108350)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Schmid P, Abraham J, Chan S, Wheatley D,
Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, et al:
Capivasertib plus paclitaxel versus placebo plus paclitaxel as
first-line therapy for metastatic triple-negative breast cancer:
The PAKT trial. J Clin Oncol. 38:423–433. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kim SB, Dent R, Im SA, Espié M, Blau S,
Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, et al:
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as
first-line therapy for metastatic triple-negative breast cancer
(LOTUS): A multicentre, randomised, double-blind,
placebo-controlled, phase 2 trial. Lancet Oncol. 18:1360–1372.
2017.PubMed/NCBI View Article : Google Scholar
|
